PCSK9 inhibitors monitoring differences?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

PCSK9 inhibitors monitoring differences?

Monitoring focus for PCSK9 inhibitors is on effectiveness and general safety, not on routine liver or muscle enzyme tests. These drugs have a low risk of hepatotoxicity and myopathy, so there is no mandatory ongoing liver function testing or CK monitoring specific to PCSK9 inhibitors. Baseline labs or tests may be done per usual clinical practice or if symptoms or other conditions arise, but routine CK or LFT checks aren’t required just because someone is on a PCSK9 inhibitor. Regular liver biopsy is not indicated.

Monitoring focus for PCSK9 inhibitors is on effectiveness and general safety, not on routine liver or muscle enzyme tests. These drugs have a low risk of hepatotoxicity and myopathy, so there is no mandatory ongoing liver function testing or CK monitoring specific to PCSK9 inhibitors. Baseline labs or tests may be done per usual clinical practice or if symptoms or other conditions arise, but routine CK or LFT checks aren’t required just because someone is on a PCSK9 inhibitor. Regular liver biopsy is not indicated.

More practice questions